NCT01931137View on ClinicalTrials.gov

A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
DiabetesHealthy
Interventions
DRUG

insulin 338 (GIPET I)

Dose level of 8100 nmol will be orally administered as one tablet per dose.

Trial Locations (1)

41460

Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY